Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Review

Patient-derived xenograft (PDX) models, applications and challenges in cancer research

Authors: Shahrokh Abdolahi, Zeinab Ghazvinian, Samad Muhammadnejad, Mahshid Saleh, Hamid Asadzadeh Aghdaei, Kaveh Baghaei

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

The establishing of the first cancer models created a new perspective on the identification and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft models are created by tumor tissue engraftment. These models accurately represent the biology and heterogeneity of different cancers and recapitulate tumor microenvironment. These features have made it a reliable model along with the development of humanized models. Therefore, they are used in many studies, such as the development of anti-cancer drugs, co-clinical trials, personalized medicine, immunotherapy, and PDX biobanks. This review summarizes patient-derived xenograft models development procedures, drug development applications in various cancers, challenges and limitations.
Literature
1.
Pott P. Chirurgical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures, and the mortification of the toes and feet, by Percivall Pott, FRS Surgeon to St. Bartholomew’s-Hospital. Printed, by TJ Carnegy, For L. Hawes, W. Clarke, and R. Collins, in Pater-noster Row; 1775.
2.
Hedrich HJ. The house mouse as a laboratory model: a historical perspective. The Laboratory Mouse. Burlington: Elsevier Science; 2012. p. 868.
3.
Johnson J, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424–31.PubMedPubMedCentralCrossRef
4.
Ellis LM, Fidler IJ. Finding the tumor copycat: therapy fails, patients don’t. Nat Med. 2010;16(9):974–5.PubMedCrossRef
5.
Rezaee R, Abdollahi M. The importance of translatability in drug discovery. Expert Opin Drug Discov. 2017;12(3):237–9.PubMedCrossRef
6.
Hutchinson L, Kirk R. High drug attrition rates—where are we going wrong? Nat Rev Clin Oncol. 2011;8(4):189–90.PubMedCrossRef
7.
Ajith A, et al. Humanized mouse model as a novel approach in the assessment of human allogeneic responses in organ transplantation. Front Immunol. 2021;12:2301.CrossRef
8.
Izumchenko E, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017;28(10):2595–605.PubMedPubMedCentralCrossRef
9.
10.
Ledford H. US cancer institute overhauls cell lines: veteran cells to be replaced by human tumours grown in mice. Nature. 2016;530(7591):391–2.PubMedCrossRef
11.
Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev. 2016;99:186–96.PubMedCrossRef
12.
Komohara Y, Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol. 2017;241(3):313–5.PubMedCrossRef
13.
14.
15.
Goto T. Patient-derived tumor xenograft models: toward the establishment of precision cancer medicine. J Pers Med. 2020;10(3):64.PubMedCentralCrossRef
16.
17.
Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 2019;8(8):889.PubMedCentralCrossRef
18.
19.
Dobrolecki LE, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–73.PubMedPubMedCentralCrossRef
20.
Wang Y, et al. Subrenal capsule grafting technology in human cancer modeling and translational cancer research. Differentiation. 2016;91(4–5):15–9.PubMedCrossRef
21.
Behbod F, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11(5):R66.PubMedPubMedCentralCrossRef
22.
Jin K, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12(7):473–80.PubMedCrossRef
23.
24.
Yao L-C, et al. Creation of pdx-bearing humanized mice to study immuno-oncology. In: Target identification and validation in drug discovery. Springer; 2019. p. 241–52.CrossRef
25.
John T, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2011;17(1):134–41.PubMedCrossRef
26.
Merk J, et al. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg. 2009;36(3):454–9.PubMedCrossRef
27.
Simpson-Abelson MR, et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγnull mice. J Immunol. 2008;180(10):7009–18.PubMedCrossRef
28.
Fichtner I, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14(20):6456–68.PubMedCrossRef
29.
Razmara AM, et al. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer. Clin Exp Metas. 2020;37(3):413–24.CrossRef
30.
Huo K-G, D’Arcangelo E, Tsao M-S. Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Transl Lung Cancer Res. 2020;9(5):2214.PubMedPubMedCentralCrossRef
31.
Yong KSM, Her Z, Chen Q. Humanized mice as unique tools for human-specific studies. Arch Immunol Ther Exp. 2018;66(4):245–66.CrossRef
32.
Tu W, Zheng J. Application of humanized mice in immunological research. In: Suppression and regulation of immune responses. New York: Springer; 2016. p. 157–76.CrossRef
33.
De La Rochere P, et al. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39(9):748–63.CrossRef
34.
Gao H, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318–25.PubMedCrossRef
35.
Oh D-Y, Bang Y-J. HER2-targeted therapies—a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.PubMedCrossRef
36.
37.
38.
Byrne AT, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17(4):254.PubMedCrossRef
39.
Evrard YA, et al. The National Cancer Institute’s patient-derived models repository (PDMR). AACR; 2017.
40.
Evrard YA, et al. The National Cancer Institute’s patient-derived models repository (PDMR). In: Cancer research. Philadelphia: AMER Assoc Cancer Research; 2018.
41.
42.
43.
44.
Nardella C, et al. The APL paradigm and the “co-clinical trial” project. AACR; 2011.
45.
Clohessy JG, Pandolfi PP. Mouse hospital and co-clinical trial project—from bench to bedside. Nat Rev Clin Oncol. 2015;12(8):491.PubMedCrossRef
46.
Nanni P, et al. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Sci Rep. 2019;9(1):1–12.CrossRef
47.
48.
Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344(1):1–12.PubMedCrossRef
49.
50.
Zhao Y, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018;67(10):1845–54.PubMedCrossRef
51.
Sanmamed MF, et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2−/− IL2Rγnull immunodeficient mice. Can Res. 2015;75(17):3466–78.CrossRef
52.
Stecklum M, et al. Abstract B126: correlation of tumor growth inhibition by check point inhibitors with PD-L1 expression in preclinical patient derived xenograft (PDX) models. AACR; 2016.
53.
Sobarzo A, et al. A36 patient-specific humanized PDX model for overcoming tumor resistance to immune checkpoint inhibitors in NSCLC patients. J Thorac Oncol. 2020;15(2):S24.CrossRef
54.
Helleday T. Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles. Ann Oncol. 2020;31(2):167–8.PubMedCrossRef
55.
Zhao Y, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Can Res. 2010;70(22):9053–61.CrossRef
56.
Mhaidly R, Verhoeyen E. Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies. Cancers. 2020;12(7):1915.PubMedCentralCrossRef
57.
Jiang H, et al. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. Protein Cell. 2017;8(12):926–31.PubMedPubMedCentralCrossRef
58.
59.
Ny L, et al. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Ann Oncol. 2020;31(2):266–73.PubMedCrossRef
60.
61.
Puchalapalli M, et al. NSG mice provide a better spontaneous model of breast cancer metastasis than athymic (nude) mice. PLoS ONE. 2016;11(9): e0163521.PubMedPubMedCentralCrossRef
62.
Wang D, et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 2017;140(3):662–73.PubMedCrossRef
63.
Ilie M, et al. Setting up a wide panel of patient-derived tumor xenografts of non–small cell lung cancer by improving the preanalytical steps. Cancer Med. 2015;4(2):201–11.PubMedCrossRef
64.
Liu C, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020;470:95–105.PubMedCrossRef
65.
Cutz J-C, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006;12(13):4043–54.PubMedCrossRef
66.
67.
68.
de Plater L, et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer. 2010;103(8):1192–200.PubMedPubMedCentralCrossRef
69.
DeRose YS, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514.PubMedPubMedCentralCrossRef
70.
Eirew P, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518(7539):422.PubMedCrossRef
71.
Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Can Res. 2015;75(15):2963–8.CrossRef
72.
73.
Zhang Y, et al. Establishing metastatic patient-derived xenograft model for colorectal cancer. Jpn J Clin Oncol. 2020;50(10):1108–16.PubMedCrossRef
74.
Puig I, et al. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin Cancer Res. 2013;19(24):6787–801.PubMedCrossRef
75.
Chou J, et al. Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. PLoS ONE. 2013;8(11): e79874.PubMedPubMedCentralCrossRef
76.
Julien S, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18(19):5314–28.PubMedCrossRef
77.
78.
Cho YB, et al. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. J Surg Res. 2014;187(2):502–9.PubMedCrossRef
79.
Kim MK, et al. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther. 2012;11(7):1500–9.PubMedPubMedCentralCrossRef
80.
Bertotti A, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–23.PubMedCrossRef
81.
Dangles-Marie V, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Can Res. 2007;67(1):398–407.CrossRef
82.
Mullins CS, et al. Integrated biobanking and tumor model establishment of human colorectal carcinoma provides excellent tools for preclinical research. Cancers. 2019;11(10):1520.PubMedCentralCrossRef
83.
Isella C, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2015;47(4):312.PubMedCrossRef
84.
Tian X, et al. 3,3’-Diindolylmethane inhibits patient-derived xenograft colon tumor growth by targeting COX1/2 and ERK1/2. Cancer Lett. 2019;448:20–30.PubMedCrossRef
85.
Weiswald L, et al. A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. Br J Cancer. 2013;108(8):1720.PubMedPubMedCentralCrossRef
86.
87.
Nguyen HM, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate. 2017;77(6):654–71.PubMedPubMedCentralCrossRef
88.
Navone NM, et al. Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018;78(16):1262–82.PubMedCrossRef
89.
Lam H-M, Nguyen HM, Corey E. Generation of prostate cancer patient-derived xenografts to investigate mechanisms of novel treatments and treatment resistance. In: Prostate cancer. New York: Springer; 2018. p. 1–27.
90.
Staack A, et al. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate. 2003;54(3):212–9.PubMedCrossRef
91.
Wang Y, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 2005;64(2):149–59.PubMedCrossRef
92.
93.
Grisanzio C, et al. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol. 2011;225(2):212–21.PubMedPubMedCentralCrossRef
94.
Risbridger GP, Lawrence MG. Towards best practice in establishing patient-derived xenografts. In: Patient-derived xenograft models of human cancer. Cham: Springer; 2017. p. 11–28.CrossRef
95.
Steinestel J, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2019;10(41):4213.PubMedCrossRef
96.
Laitinen S, et al. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosom Cancer. 2002;35(1):66–73.PubMedCrossRef
97.
Hausser H-J, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun. 2005;333(1):216–22.PubMedCrossRef
98.
Murphy B, et al. Evaluation of alternative in vivo drug screening methodology: a single mouse analysis. Can Res. 2016;76(19):5798–809.CrossRef
99.
Keysar SB, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013;7(4):776–90.PubMedPubMedCentralCrossRef
100.
101.
Jin K, et al. Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. Hepatogastroenterology. 2011;58(110–111):1814–22.PubMed
102.
Read M, et al. Intramuscular transplantation improves engraftment rates for esophageal patient-derived tumor xenografts. Ann Surg Oncol. 2016;23(1):305–11.PubMedCrossRef
103.
Fujii E, et al. Establishment and characterization of in vivo human tumor models in the NOD/SCID/γcnull mouse. Pathol Int. 2008;58(9):559–67.PubMedCrossRef
104.
Zhang T, et al. Patient-derived gastric carcinoma xenograft mouse models faithfully represent human tumor molecular diversity. PLoS ONE. 2015;10(7): e0134493.PubMedPubMedCentralCrossRef
105.
Zhang L, et al. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. Sci Rep. 2015;5:9447.PubMedPubMedCentralCrossRef
106.
Vockerodt M, et al. The Epstein–Barr virus and the pathogenesis of lymphoma. J Pathol. 2015;235(2):312–22.PubMedCrossRef
107.
Petrillo LA, et al. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat. 2012;135(3):913–22.PubMedCrossRef
108.
Sprouffske K, et al. Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models. Comput Struct Biotechnol J. 2020;18:323–31.PubMedPubMedCentralCrossRef
109.
Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet. 2015;16(7):373.PubMedCrossRef
110.
Wang M, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018;32(3):1537–49.PubMedCrossRef
111.
Cho S-Y. Patient-derived xenografts as compatible models for precision oncology. Lab Anim Res. 2020;36(1):1–11.CrossRef
112.
Covassin L, et al. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2r γnull (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin Exp Immunol. 2013;174(3):372–88.PubMedPubMedCentralCrossRef
113.
Kalavska K, et al. Lymphoma transformation of tumor infiltrating lymphocytes observed in testicular patient-derived xenograft models. Oncol Rep. 2018;40(6):3593–602.PubMed
114.
Choi YY, et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep. 2016;6(1):1–12.
115.
Wetterauer C, et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate. 2015;75(6):585–92.PubMedCrossRef
116.
117.
118.
Liu Y, et al. Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. Quant Imaging Med Surg. 2015;5(5):708.PubMedPubMedCentral
119.
120.
Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006;5(9):741–54.PubMedCrossRef
121.
Georges LMC, et al. Cell line derived xenograft mouse models are a suitable in vivo model for studying tumor budding in colorectal cancer. Front Med. 2019;6:139.CrossRef
122.
Jung J, Seol HS, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat. 2018;50(1):1.PubMedCrossRef
123.
124.
Liu WN, et al. Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy. Cancers. 2020;12(4):1025.PubMedCentralCrossRef
125.
Marangoni E, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989–98.PubMedCrossRef
126.
Zhang X, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Can Res. 2013;73(15):4885–97.CrossRef
127.
Nunes M, et al. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Can Res. 2015;75(8):1560–6.CrossRef
128.
Ricci F, et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Can Res. 2014;74(23):6980–90.CrossRef
129.
Huynh H, Ong R, Zopf D. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. J Exp Clin Cancer Res. 2015;34(1):132.PubMedPubMedCentralCrossRef
130.
Zhang X-C, et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med. 2013;11(1):168.PubMedPubMedCentralCrossRef
131.
Garrido-Laguna I, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011;17(17):5793–800.PubMedPubMedCentralCrossRef
132.
Nehls M, et al. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature. 1994;372(6501):103.PubMedCrossRef
133.
Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood J Am Soc Hematol. 2015;125(17):2630–40.
134.
Blunt T, et al. Defective DNA-dependent protein kinase activity is linked to V (D) J recombination and DNA repair defects associated with the murine scid mutation. Cell. 1995;80(5):813–23.PubMedCrossRef
135.
Nonoyama S, et al. Strain-dependent leakiness of mice with severe combined immune deficiency. J Immunol. 1993;150(9):3817–24.PubMed
136.
Greiner DL, et al. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with CB-17-scid/scid mice. Am J Pathol. 1995;146(4):888.PubMedPubMedCentral
137.
Christianson SW, et al. Role of natural killer cells on engraftment of human lymphoid cells and on metastasis of human T-lymphoblastoid leukemia cells in C57BL/6J-scidMice and in C57BL/6J-scid bgMice. Cell Immunol. 1996;171(2):186–99.PubMedCrossRef
138.
Shultz LD, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154(1):180–91.PubMed
139.
Pflumio F, et al. Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood. 1996;88(10):3731–40.PubMedCrossRef
140.
Richard E, et al. The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. J Pathol. 2016;240(3):256–61.PubMedCrossRef
141.
Shultz LD, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477–89.PubMedCrossRef
142.
Jung YJ, et al. Development of a protein biomarker panel to detect non-small-cell lung cancer in Korea. Clin Lung Cancer. 2017;18(2):e99–107.PubMedCrossRef
143.
Morgan KM, et al. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front Oncol. 2017;7:2.PubMedPubMedCentralCrossRef
144.
Jiang Y, et al. Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. J Transl Med. 2018;16(1):138.PubMedPubMedCentralCrossRef
145.
Kuwata T, et al. Establishment of novel gastric cancer patient-derived xenografts and cell lines: pathological comparison between primary tumor, patient-derived, and cell-line derived xenografts. Cells. 2019;8(6):585.PubMedCentralCrossRef
146.
Wang Y, Lin D, Gout PW. Patient-derived xenograft models of human cancer. Cham: Springer; 2017.CrossRef
147.
Du Manoir S, et al. Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol. 2014;8(2):431–43.PubMedCrossRef
Metadata
Title
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Authors
Shahrokh Abdolahi
Zeinab Ghazvinian
Samad Muhammadnejad
Mahshid Saleh
Hamid Asadzadeh Aghdaei
Kaveh Baghaei
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03405-8

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Body mass index, genetic susceptibility, and Alzheimer's disease: a longitudinal study based on 475,813 participants from the UK Biobank

Research

Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer

Research

Characterization of the effect of histone deacetylation inhibitors on CD8+ T cells in the context of aging

Research

SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization

Research

Comparison of dynamic susceptibility contrast enhanced MR and FDG-PET brain studies in patients with Alzheimer’s disease and amnestic mild cognitive impairment

Research

Harm of circadian misalignment to the hearts of the adolescent wistar rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits